La catena delle opzioni mostra i dati chiave delle opzioni azionarie di SIGNA Sports United a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per SIGNA Sports United..

SIGNA Sports United (OTC:SSUNF) Azioni, Catena delle Opzioni

SIGNA Sports United NV is a group of specialist sports webshops powered by its sports commerce and technology platform. The company's segment includes Tennis; Bike and Outdoor and Teamsport. It generates maximum revenue from the Bike and Outdoor segment. Geographically, it derives a majority of revenue from Germany.

SIGNA SPORTS UNITED N.V. by SIGNA Sports United N.V.

SIGNA Sports United NV

6 analysts have expressed a variety of opinions on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ocular Therapeutix and provided 12-month price targets. The average target is $15.83, accompanied by a high estimate of $19.00 and a low estimate of $14.00. This current average represents a 5.49% decrease from the previous average price target of $16.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532874_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Ocular Therapeutix by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ocular Therapeutix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ocular Therapeutix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ocular Therapeutix's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ocular Therapeutix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Ocular Therapeutix Better</h2>
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
<h3>Understanding the Numbers: Ocular Therapeutix's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Ocular Therapeutix's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.41% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocular Therapeutix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -283.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ocular Therapeutix's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -14.5%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ocular Therapeutix's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.21%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OCUL

Analyst Expectations For Ocular Therapeutix's Future

Hovde Group analyst Brendan Nosal upgrades HBT Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBT#NASDAQ">HBT</a>) from Market Perform to Outperform.

News

Upgrades

Hovde Group Upgrades HBT Finl to Outperform

Throughout the last three months, 8 analysts have evaluated Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Navitas Semiconductor and provided 12-month price targets. The average target is $3.94, accompanied by a high estimate of $5.00 and a low estimate of $1.50. A 7.51% drop is evident in the current average compared to the previous average price target of $4.26. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532857_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Navitas Semiconductor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.50</td>
<td>$2.10</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Navitas Semiconductor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Navitas Semiconductor compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Navitas Semiconductor's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVTS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Navitas Semiconductor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Navitas Semiconductor</h2>
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.
<h3>Breaking Down Navitas Semiconductor's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Navitas Semiconductor's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -31.01% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Navitas Semiconductor's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -221.72%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -10.94%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Navitas Semiconductor's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.85%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Navitas Semiconductor's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVTS

A Glimpse Into The Expert Outlook On Navitas Semiconductor Through 8 Analysts

Analysts' ratings for EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated EZCORP and provided 12-month price targets. The average target is $18.88, accompanied by a high estimate of $24.00 and a low estimate of $13.50. Observing a downward trend, the current average is 1.51% lower than the prior average price target of $19.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532842_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of EZCORP by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kyle Joseph</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$13.50</td>
<td>$13.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EZCORP. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of EZCORP compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for EZCORP's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into EZCORP's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EZPW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EZCORP analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About EZCORP</h2>
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
<h3>Key Indicators: EZCORP's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: EZCORP's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 7.24%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: EZCORP's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): EZCORP's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.03%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): EZCORP's ROA stands out, surpassing industry averages. With an impressive ROA of 1.53%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: EZCORP's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EZPW

Analyst Expectations For EZCORP's Future

Ratings for Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $162.95, with a high estimate of $185.00 and a low estimate of $137.00. This current average has decreased by 4.65% from the previous average price target of $170.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532832_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Neurocrine Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$168.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$137.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$184.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$148.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$179.00</td>
<td>$184.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Neurocrine Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Neurocrine Biosciences: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 21.84%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NBIX

What 19 Analyst Ratings Have To Say About Neurocrine Biosciences

WIIM

SHLS

Shoals Technologies Group shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance above estimates.

In the latest quarter, 4 analysts provided ratings for Cable One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $359.25, with a high estimate of $650.00 and a low estimate of $222.00. Observing a downward trend, the current average is 24.76% lower than the prior average price target of $477.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532823_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Cable One's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sebastiano Petti</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$222.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Sebastiano Petti</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$325.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$240.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$650.00</td>
<td>$825.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cable One. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cable One compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cable One's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cable One's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CABO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cable One analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Cable One Better</h2>
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.
<h3>Unraveling the Financial Story of Cable One</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Cable One faced challenges, resulting in a decline of approximately -5.86% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.
Net Margin: Cable One's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 0.69%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Cable One's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.15%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Cable One's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.04%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 2.0, Cable One adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CABO

Expert Outlook: Cable One Through The Eyes Of 4 Analysts

4 analysts have shared their evaluations of Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Artivion, revealing an average target of $31.75, a high estimate of $33.00, and a low estimate of $30.00. This current average represents a 3.79% decrease from the previous average price target of $33.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532815_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Artivion. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Artivion compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Artivion's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Artivion's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AORT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Artivion analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Artivion</h2>
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
<h3>Artivion: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Artivion's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.88%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -16.91%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Artivion's ROE stands out, surpassing industry averages. With an impressive ROE of -5.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Artivion's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.07% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.31, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AORT

What Analysts Are Saying About Artivion Stock

Hovde Group analyst Brendan Nosal upgrades Lakeland Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKFN#NASDAQ">LKFN</a>) from Market Perform to Outperform.

LKFN

Hovde Group Upgrades Lakeland Financial to Outperform

EVGO

EVgo shares are trading higher after the company reported better-than-expected Q1 sales results and issued FY25 sales guidance with its midpoint above estimates.

Piper Sandler analyst Harsh Kumar has projected a potential data center annual revenue loss of $9.8 billion for Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) due to a slowdown in capital expenditure (capex) and an ongoing decoupling from China.
What Happened:&nbsp;Kumar&#8217;s latest sensitivity analysis indicates a &#8220;worst case&#8221; scenario where NVIDIA&#8217;s data center revenues could suffer a significant blow, amounting to 6.45% of the company&#8217;s total annual revenue from this segment. This could result in an EPS hit of around $0.40, according to a report by&nbsp;<a href="https://wccftech.com/piper-sandler-sees-nvidia-taking-a-10-billion-hit-annually-from-ai-related-capex-slowdown-and-the-decoupling-from-china/">Wccftech</a>. 
Kumar&#8217;s worst-case scenario estimates NVIDIA shares could drop to $76.25, based on a 25x earnings multiple. In contrast, Piper Sandler&#8217;s best-case outlook sets a target of $126.75. At present, NVIDIA stock is trading slightly below $114.
This analysis comes after a separate study by&nbsp;market research firm TechInsights, which&nbsp;pointed out alarming signs for the wider semiconductor industry amidst ongoing tariff-related tensions between the U.S. and China. TechInsights anticipates a potential 10% contraction in the global semiconductor market by 2025 if the current tariff rates persist.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45191793/shiba-inu-drops-10-in-7-days-what-is-going-on" target="_blank" rel="noreferrer noopener">Shiba Inu Drops 10% In 7 Days: What Is Going On? &#8211; Benzinga</a>
Why It Matters: The projected loss comes in the wake of NVIDIA&#8217;s ongoing efforts to redesign artificial intelligence chips for major Chinese tech firms. This move was prompted by the potential multibillion-dollar losses that could <a href="https://www.benzinga.com/25/05/45182565/nvidia-designing-new-ai-chips-for-alibaba-bytedance-tencent-after-warning-us-export-ban-on-h20-could-cost-the-company-55-billion-report">result </a>from tightened U.S. export restrictions on its H20 chip in April.
NVIDIA previously stated it anticipates taking charges of up to $5.5 billion in fiscal Q1 2026 due to &#8220;inventory, purchase commitments, and related reserves&#8221; tied to its China-specific H20 GPU.
After the Trump administration imposed curbs on H20 AI chips, CEO Jensen Huang travelled to Beijing and met Chinese officials.
Furthermore, China&#8217;s search for domestic alternatives to NVIDIA&#8217;s H20 chip has led to Huawei Technologies preparing to start mass shipments of its advanced 910C artificial intelligence chip to Chinese customers, as <a href="https://www.benzinga.com/25/04/44897966/huawei-prepares-for-bulk-shipment-of-new-advanced-ai-chip-as-china-seeks-nvidia-alternatives">reported</a>&nbsp;in April 2025. This move by Huawei could further impact NVIDIA&#8217;s market share and revenue in China.
Nvidia stock slid 0.59% to close at $113.82 on Monday. On a year-to-date basis, it lost more than 17%, as per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45187736/elizabeth-warren-slams-shady-deal-involving-trump-family-backed-usd1-as-democrats-withdraw-support-for-senarte-crypto-bill" target="_blank" rel="noreferrer noopener">Elizabeth Warren Slams &#8216;Shady&#8217; Deal Involving Trump Family-Backed USD1 As Democrats Withdraw Support For Senarte Crypto Bill &#8211; Benzinga</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Markets

Tech

NVDA

Nvidia Risks Losing Up To $10 Billion In Annual Data Center Revenue Amid CapEx Slowdown, China Decoupling, Warns Analyst

AMETEK To Acquire FARO Technologies For $44/Share In $920M Deal, Marking 40% Premium And Expanding 3D Measurement Portfolio

CSTL

Castle Biosciences shares are trading lower after the company reported mixed Q1 financial results. The company signed an agreement to acquire Capsulomics.

Order reflects growing demand for ParaZero's advanced drone safety solutions across the European commercial and enterprise sectors
TEL AVIV, Israel, May 06, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "company" or "ParaZero"), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems, today announced that it has received a new order for dozens of units of its innovative SafeAir&#x2122; M4 system. The order was placed by a prominent European drone distributor that serves a wide range of commercial, public safety, and enterprise drone operators across the region.

PRZO

ParaZero Technologies Receives New Order For Dozens Of Units Of SafeAir M4 System

SEAT

Vivid Seats shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, the company announced that it is suspending its FY25 guidance due to global economic uncertainty.

International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) on Tuesday disclosed a collaboration with Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to integrate IBM&#8217;s premier AI platform, Watsonx, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45213081/ibm-and-oracle-expand-partnership-to-advance-agentic-ai-and-hybrid-cloud" rel="noreferrer noopener">with Oracle Cloud Infrastructure (OCI)</a>.
This latest development in their partnership aims to leverage OCI&#8217;s built-in AI capabilities to foster a new wave of AI-powered productivity and efficiency across businesses, particularly through multi-agentic systems.
IBM&#8217;s Watsonx Orchestrate AI agents will be available on OCI in July, integrating with Oracle&#8217;s AI Agent Studio and OCI AI services for unified multi-agent management across Oracle and non-Oracle systems.
Initially focused on HR, watsonx Orchestrate on OCI (Red Hat OpenShift) supports various cloud regions and hybrid deployments, performing AI inferencing on OCI.
Greg Pavlik, executive vice president, AI and Data Management Services, Oracle Cloud Infrastructure, said, &#8220;IBM and Oracle have been collaborating to drive customer success for decades, and our expanded partnership will provide customers new ways to help transform their businesses with AI.&#8221;
In a separate release, IBM introduced new hybrid cloud technologies designed to overcome traditional <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45213085/ibm-accelerates-enterprise-gen-ai-revolution-with-hybrid-capabilities" rel="noreferrer noopener">obstacles in scaling enterprise AI</a>.
The company projects that the app landscape will explode to over a billion by 2028, intensifying the pressure on organizations to achieve scalability across increasingly complex and fragmented IT ecosystems.
In April, the company disclosed a&nbsp;$150 billion&nbsp;investment plan in the U.S.&nbsp;over the next five years to drive economic growth and strengthen its <a target="_blank" href="https://www.benzinga.com//node/45041909" rel="noreferrer noopener">position as a global computing leader</a>.
Investors can gain exposure to the stock via&nbsp;First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>) and&nbsp;FT Vest Technology Dividend Target Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TDVI#BATS">TDVI</a>).
Price Action: IBM shares are down 0.59% at $247.70 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44987653/ibms-shares-drop-sharply-after-q1-report-analysts-say-its-overdone-revenue-growth-to-accelerate" target="_blank" rel="noreferrer noopener">IBM&#8217;s Shares Drop Sharply After Q1 Report: Analysts Say It&#8217;s Overdone, Revenue Growth To Accelerate</a></li>
</ul>
Photo via Shutterstock

Equities

Large Cap

Contracts

ORCL

TDIV

TDVI

IBM AI Watsonx Integrates With Oracle Cloud To Boost Enterprise Productivity

Stephens &amp; Co. analyst Matt Olney initiates coverage on Firstsun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) with a Overweight rating and announces Price Target of $44.

Price Target

Initiation

FSUN

Stephens & Co. Initiates Coverage On Firstsun Capital Bancorp with Overweight Rating, Announces Price Target of $44

JP Morgan analyst Andrea Teixeira maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $151 to $144.

JP Morgan Maintains Neutral on Clorox, Lowers Price Target to $144

ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) reported better-than-expected fiscal <a href="https://www.benzinga.com/quote/ON/earnings">first-quarter 2025 results on Monday</a>.
The company reported a quarterly revenue decline of 22.4% year-on-year to $1.45 billion, topping the analyst consensus estimate of $1.40 billion. The adjusted EPS of $0.55 beat the analyst consensus estimate of $0.51.
&#8220;Our results in the first quarter reflect the disciplined approach we have maintained through this downturn – managing our cost structure, right-sizing our manufacturing footprint, and rationalizing our portfolio – enabling us to generate increased free cash flow. We are committed to long-term value creation and we are accelerating our capital return to shareholders while investing in our future growth,&#8221; said Hassane El-Khoury, president and CEO, onsemi. &#8220;We continue to see strong design win momentum, driven by the industry-leading performance of our products and have secured key wins with major global customers across all end-markets.&#8221;
ON Semiconductor expects second-quarter adjusted revenue of $1.40 billion—$1.45 billion, compared to the analyst consensus estimate of $1.42 billion. The company expects quarterly adjusted EPS of $0.48–$0.58 (above the analyst consensus estimate of $0.45) and an adjusted gross margin of 36.5%-38.5%.
ON Semiconductor shares dipped 8.4% to close at $38.41 on Monday.
These analysts made changes to their price targets on ON Semiconductor following earnings announcement.
<ul>
<li>Needham analyst Quinn Bolton maintained ON Semiconductor with a Buy and lowered the price target from $57 to $50.</li>
<li>Benchmark analyst David Williams maintained ON Semiconductor with a Buy and lowered the price target from $60 to $50.</li>
<li>Rosenblatt analyst Kevin Cassidy maintained the stock with a Neutral and maintained a $42 price target.</li>
</ul>
Considering buying ON stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06075417/image-2-20-1024x592.png" alt="" class="wp-image-903081" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06075417/image-2-20-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06075417/image-2-20-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06075417/image-2-20-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06075417/image-2-20.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Comments

SIGNA Sports United

SIGNA Sports United (SSUNF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO